CDT EQUITY INC. Entity Listing, Par Value Per Share
CDT EQUITY INC. (CDT) reported Entity Listing, Par Value Per Share of $0.00 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Cover Page
dei:EntityListingParValuePerShare · last filed 2026-08-12
- CDT EQUITY INC. entity listing, par value per share for the quarter ending 2026-03-31 was $0.00, a 0.00% change year-over-year.
- CDT EQUITY INC. entity listing, par value per share for the quarter ending 2025-03-31 was $0.00.
- CDT EQUITY INC. entity listing, par value per share for fiscal 2025 was $0.00, a 0.00% change from fiscal 2024.
- CDT EQUITY INC. entity listing, par value per share for fiscal 2024 was $0.00.
| Period end | Entity Listing, Par Value Per Share 3 month | Entity Listing, Par Value Per Share 6 month | Entity Listing, Par Value Per Share 9 month | Entity Listing, Par Value Per Share 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 10-Q · filed 2026-08-12 | |||
| 2026-03-31 | $0.00 10-Q · filed 2026-07-15 | |||
| 2025-12-31 | $0.00 10-K · filed 2026-04-15 | |||
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | |||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-14 | |||
| 2025-03-31 | $0.00 10-Q/A · filed 2025-08-14 | |||
| 2024-12-31 | $0.00 10-K · filed 2025-03-28 | |||
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $0.00 10-Q/A · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |